(E)-1-[2-hydroxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-3-[4-hydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: (E)-1-[2-hydroxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-3-[4-hydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one
• 化学式: C₂₇H₃₂O₁₅
• 分子量: 596.5
• InChiKey: XOTWNDIAAITUKR-ORCRQEGFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  42
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  256
• 氢给体数：
  10
• 氢受体数：
  15

文献信息

• Pharmaceutical composition containing substance inhibiting HSP47 production
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：EP0742012A2

  公开（公告）日：1996-11-13

  A pharmaceutical composition comprising a substance inhibiting HSP47 production, selected from the group consisting of a malt extract, a flavonoid compound, a protein-bound-polysaccharide obtained from a fungus belonging to Coriolus versicolor, a paeoniflorin derivative, a tocopherol derivative, and a ferulic acid derivative, and a pharmaceutically acceptable carrier is disclosed. The substance inhibiting HSP47 production can efficiently improve physiological conditions of a patient suffering from diseases exhibiting pathosis of overproduction of the extracellular matrix, and efficiently treat such diseases. Further, the substance is useful for preventing or treating various diseases accompanied with abnormal growth of the vascularization.

  本发明公开了一种药物组合物，该组合物包含一种抑制 HSP47 生成的物质，该物质选自麦芽提取物、黄酮类化合物、从属于 Coriolus versicolor 的真菌中获得的蛋白结合多糖、芍药苷衍生物、生育酚衍生物和阿魏酸衍生物组成的组，以及一种药学上可接受的载体。这种抑制 HSP47 生成的物质可以有效改善患有细胞外基质过度生成病症的患者的生理状况，并有效治疗此类疾病。此外，该物质还可用于预防或治疗伴有血管异常生长的各种疾病。
• Pharmaceutical unit dosage form comprising 4-phenylbutyric acid
  申请人：Lunamed AG

  公开号：EP2698155A1

  公开（公告）日：2014-02-19

  The invention provides a pharmaceutical unit dosage form comprising 4-phenylbutyric acid (4-PB) as a free acid or as a salt; as a prodrug, a codrug, a co-crystal or any salt or hydrate or solvate thereof. The invention further provides the use of said pharmaceutical dosage form for the prevention or treatment of cancer and methods for preparing said pharmaceutical dosage form.

  本发明提供了一种包含 4-苯基丁酸（4-PB）的药物单位剂型，4-苯基丁酸（4-PB）可以是游离酸或盐；也可以是原药、复方药、共晶体或其任何盐或水合物或溶液。本发明进一步提供了所述药物剂型用于预防或治疗癌症的用途以及制备所述药物剂型的方法。
• Phenylbutyric acid for chemoprevention
  申请人：Lunamed AG

  公开号：EP2698156A1

  公开（公告）日：2014-02-19

  The invention provides a pharmaceutical composition comprising phenylbutyric acid, a derivative, a prodrug, solvate or a physiologically acceptable salt thereof for use in the prevention of cancer. Furthermore pharmaceutical compositions are disclosed which comprise a further chemopreventive agent.

  本发明提供了一种包含苯丁酸、其衍生物、原药、溶液或生理上可接受的盐的药物组合物，用于预防癌症。此外，本发明还公开了包含另一种化学预防剂的药物组合物。
• Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
  申请人：COOK MEDICAL TECHNOLOGIES LLC

  公开号：US10016536B2

  公开（公告）日：2018-07-10

  Various aspects of the present invention provide compositions and implantable devices including a water-insoluble therapeutic agent solubilized in a matrix of a gallate-containing compound. Other aspects provide methods of manufacturing and using such compositions and devices.

  本发明的各个方面提供了包括溶解在含没食子酸盐化合物基质中的水不溶性治疗剂的组合物和可植入装置。其他方面还提供了制造和使用这种组合物和装置的方法。
• Flavonoide esters and their use notably in cosmetics
  申请人：COLETICA

  公开号：US20010031735A1

  公开（公告）日：2001-10-18

  The invention relates to a flavonoid ester. This flavonoid ester results from the reaction product of at least one flavonoid selected from the group consisting of a flavonoid with a ketone group in the 4-position, a salt, ester or ether of such a flavonoid, and a C-heteroside and/or O-heteroside derivative of such a flavonoid, with the proviso that this flavonoid contains at least one free alcohol group, with an organic monoacid having from 3 to 30 carbon atoms. These flavonoid esters constitute useful active principles for the manufacture of cosmetic, dermopharmaceutical, pharmaceutical, dietetic or agri-foodstuff compositions.

  本发明涉及一种黄酮酯。 这种类黄酮酯由至少一种类黄酮与具有 3 至 30 个碳原子的有机单酸反应生成，这些类黄酮选自在 4 位上具有酮基的类黄酮、这种类黄酮的盐、酯或醚，以及这种类黄酮的 C- 甾体苷和/或 O- 甾体苷衍生物，但这种类黄酮至少含有一个游离醇基。 这些类黄酮酯是制造化妆品、皮肤药剂、药品、食品或农业食品组合物的有效活性成分。